title: [Apoptotic mechanism of gecko crude peptides on human liver carcinoma cell line HepG2].
abstract: OBJECTIVE
  To investigate the effect of Gecko crude peptides (GCPS) on human liver carcinoma HepG2 cells and its mechanism.
  
  
  METHODS
  MTT assay was used to analyze the effect of the GCPS on the proliferation of HepG2 Cell; Nucleus change of HepG2 treated with GCP was observed by Hoechst33258 fluorescence staining, and BAX and BCL-2 were detected with western-blot assay.
  
  
  RESULTS
  GCPS could inhibit the proliferation of HepG2 Cell in a time and dosage dependent way, and its half-maximal inhibitory concentration (IC50) was 1.2 mg/mL; HepG2 pretreated with GCPS showed apoptotic morphological changes. GCPS (1.6 mg/mL, 0.8 mg/mL) could decrease the expression of BCL-2 protein, and increase the expression of BAX protein.
  
  
  CONCLUSIONS
  GCPS can inhibit the proliferation of HepG2 cell. The mechanism may be related to the induction apoptosis of HepG2.
authors.affiliation: Medical School and the Key Laboratory of Pharmacology and Medical Molecular Biology, Henan University of Science and Technology, Luoyang 471003, China. SYing2009@126.com
authors.forename: Ying
authors.initials: Y
authors.lastname: Song
authors.forename: Jian-Gang
authors.initials: JG
authors.lastname: Wang
authors.forename: Chao-Chu
authors.initials: CC
authors.lastname: Cui
authors.forename: Xin
authors.initials: X
authors.lastname: Qian
authors.forename: Rui-Fang
authors.initials: RF
authors.lastname: Li
authors.forename: Leng-Xin
authors.initials: LX
authors.lastname: Duan
authors.forename: Ling
authors.initials: L
authors.lastname: Liu
authors.forename: Shou-Min
authors.initials: SM
authors.lastname: Xi
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D015153:Blotting, Western; D049109:Cell Proliferation / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D056945:Hep G2 Cells; D006801:Humans; D008116:Lizards; D008419:Materia Medica / Q000494:pharmacology*; D010455:Peptides / Q000494:pharmacology*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D013194:Staining and Labeling / Q000379:methods; D013997:Time Factors; D051028:bcl-2-Associated X Protein / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D008419:Materia Medica; D010455:Peptides; D019253:Proto-Oncogene Proteins c-bcl-2; D051028:bcl-2-Associated X Protein